Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solana Company (NASDAQ: HSDT) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and other required reports. These documents offer detailed insight into Solana Company’s dual focus as a neurotech medical device issuer and a Solana-centric digital asset treasury.
In its filings, Solana Company describes its operations in the electromedical and electrotherapeutic apparatus manufacturing industry and outlines its orally applied technology platform for neurologic deficits. Quarterly and annual reports, such as the Form 10-K and Form 10-Q, present financial statements, revenue components (including staking rewards and other revenue), operating expenses, research and development costs, and unrealized gains or losses on digital assets.
Current reports on Form 8-K document material events, including the name change from Helius Medical Technologies, Inc. to Solana Company, the adoption of a Solana-focused digital asset treasury, PIPE financings, warrant issuances, stock repurchase authorizations, changes in independent registered public accounting firms, and board and governance developments. Proxy materials on Schedule 14A describe matters submitted to stockholders, such as director elections, equity incentive plan amendments, and approvals related to cryptocurrency-linked warrants.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex items such as derivative liabilities tied to stapled warrants, digital asset treasury activities, or auditor changes. Users can review real-time updates from EDGAR, track quarterly (10-Q) and annual (10-K) reports, and examine Form 4 and related disclosures of insider transactions where available, all supported by concise AI explanations that clarify terminology and context.
Helius Medical Technologies (Nasdaq: HSDT) filed an 8-K disclosing a 1-for-50 reverse stock split approved by shareholders and the board to regain compliance with Nasdaq’s minimum-bid requirement.
The split becomes effective at 5:00 p.m. ET on June 30 2025; trading will begin on a split-adjusted basis on July 1 2025. Outstanding shares will fall from roughly 33.8 million to 0.7 million, while authorized shares remain 150 million and par value stays $0.001.
- Fractional shares: rounded down for cash or rounded up to a whole share.
- Equity awards and warrants will be proportionally adjusted.
- New CUSIP: 42328V 876; transfer agent: Equiniti Trust.
The action, reported under Items 3.03 and 5.03, materially modifies holder rights and aims to avert a potential Nasdaq delisting.
Helius Medical Technologies, Inc. (Nasdaq: HSDT) filed a Form 8-K on June 23, 2025 to update investors on its Nasdaq listing status.
• Background: On March 31, 2025 Nasdaq Staff notified Helius that its stockholders’ equity had fallen below the required US$2.5 million, triggering a potential delisting under Listing Rule 5550(b)(1). After a subsequent hearing, Nasdaq granted the Company an extension until June 30, 2025 to regain compliance.
• Capital raise: Helius completed a public offering on June 6, 2025, generating net proceeds of approximately US$8.1 million.
• Current status: The Company has furnished an unaudited interim consolidated balance sheet dated June 17, 2025 that gives effect to the offering. Management states that the pro-forma balance sheet shows stockholders’ equity of at least US$2.5 million, which it believes restores compliance with the Nasdaq Stockholders’ Equity Requirement.
• Next steps: Helius is awaiting formal confirmation from Nasdaq that all continued-listing criteria— including the equity threshold—have been satisfied.
No earnings figures, segment data, or other financial statements were provided beyond the balance-sheet reference.
Helius Medical Technologies (NASDAQ: HSDT) has reported a significant amendment to its 2022 Equity Incentive Plan following stockholder approval at a special meeting held on May 23, 2025. The amendment, initially adopted by the Board on April 22, 2025, has resulted in a substantial increase in the company's equity compensation pool.
Key developments:
- The Plan's share pool increased to 7.1 million shares on June 16, 2025
- The increase represents 20% of Fully Diluted Shares following the company's first registered offering after May 15, 2025
- The amendment was triggered by the completion of a Public Offering
This expansion of the equity incentive plan suggests Helius Medical Technologies is strengthening its ability to attract and retain talent through equity-based compensation. The significant increase in available shares indicates the company's commitment to aligning employee interests with shareholder value.